Showing results (81-90 of 159) with videos related to

Sort By:
Pageof 16
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 14, 2015
Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosisEtienne Garin, Yan Rolland, Julien Edeline, et al.
Therapeutic Advances in Medical Oncology|August 5, 2021
FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinomaAntonin Vary, Loïc Lebellec, Frédéric Di Fiore, et al.
Investigational New Drugs|November 13, 2012
A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumorsThierry Lesimple, Julien Edeline, Timothy J Carrothers, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 13, 2015
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosisJulien Edeline, Laurence Crouzet, Boris Campillo-Gimenez, et al.
British Journal of Cancer|January 30, 2022
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO studySonia Zaibet, Vincent Hautefeuille, Edouard Auclin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 28, 2017
Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinomaXavier Palard, Julien Edeline, Yan Rolland, et al.
Endocrine-Related Cancer|July 15, 2016
Ki-67 index and response to chemotherapy in patients with neuroendocrine tumoursAlexa Childs, Amy Kirkwood, Julien Edeline, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 22, 2018
A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapyVincent Manceau, Xavier Palard, Yan Rolland, et al.
Targeted Oncology|August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric CancersBernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.
European Journal of Gastroenterology & Hepatology|December 24, 2015
Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter studyXavier Adhoute, Guillaume Pénaranda, Jean L Raoul, et al.
Pageof 16